Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) PT at $35.21

Dyne Therapeutics, Inc. (NASDAQ:DYN) has been given an average recommendation of “Moderate Buy” by the seventeen research firms that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, eleven have given a buy recommendation and three have assigned a strong buy recommendation to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $35.00.

A number of research firms have commented on DYN. Sanford C. Bernstein lifted their target price on shares of Dyne Therapeutics from $23.00 to $24.00 and gave the stock a “market perform” rating in a research report on Wednesday, May 13th. JPMorgan Chase & Co. cut their price objective on Dyne Therapeutics from $17.00 to $16.00 and set a “neutral” rating for the company in a report on Tuesday, January 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a report on Monday, April 20th. Chardan Capital reaffirmed a “buy” rating and issued a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Finally, Evercore set a $33.00 price objective on Dyne Therapeutics in a report on Friday.

Insider Transactions at Dyne Therapeutics

In related news, CFO Erick Lucera sold 1,448 shares of Dyne Therapeutics stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $18.36, for a total value of $26,585.28. Following the completion of the sale, the chief financial officer owned 123,925 shares of the company’s stock, valued at $2,275,263. The trade was a 1.15% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Jason P. Rhodes sold 83,219 shares of Dyne Therapeutics stock in a transaction on Wednesday, May 6th. The stock was sold at an average price of $18.18, for a total value of $1,512,921.42. Following the completion of the sale, the director directly owned 7,962 shares of the company’s stock, valued at $144,749.16. The trade was a 91.27% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 1,559,462 shares of company stock worth $29,814,746. 14.14% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Dyne Therapeutics

A number of hedge funds have recently modified their holdings of DYN. AQR Capital Management LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $246,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Dyne Therapeutics by 5.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 56,466 shares of the company’s stock valued at $597,000 after acquiring an additional 2,886 shares during the period. Goldman Sachs Group Inc. grew its position in shares of Dyne Therapeutics by 58.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 994,886 shares of the company’s stock valued at $10,407,000 after acquiring an additional 366,183 shares during the period. Caxton Associates LLP bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $157,000. Finally, Creative Planning grew its position in shares of Dyne Therapeutics by 23.8% during the 2nd quarter. Creative Planning now owns 14,541 shares of the company’s stock valued at $138,000 after acquiring an additional 2,797 shares during the period. Institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Stock Performance

Shares of DYN stock opened at $16.54 on Thursday. The company has a 50 day moving average price of $18.36 and a 200-day moving average price of $18.53. Dyne Therapeutics has a 52 week low of $8.06 and a 52 week high of $25.00. The firm has a market capitalization of $2.73 billion, a PE ratio of -5.14 and a beta of 1.08. The company has a quick ratio of 19.92, a current ratio of 19.92 and a debt-to-equity ratio of 0.17.

Dyne Therapeutics (NASDAQ:DYN) last announced its quarterly earnings results on Monday, May 11th. The company reported ($0.73) EPS for the quarter, topping analysts’ consensus estimates of ($0.77) by $0.04. During the same quarter in the prior year, the business earned ($1.05) earnings per share. As a group, equities research analysts expect that Dyne Therapeutics will post -2.99 earnings per share for the current year.

Dyne Therapeutics Company Profile

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.